Current Insights into Immunotherapy Approaches for Food Allergy

References

• Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2(1):e185630. doi:10.1001/jamanetworkopen.2018.5630
   PubMed Web of Science ®Google Scholar
• Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235. doi:10.1542/peds.2018-1235
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72(8):1133–1147. doi:10.1111/all.13124
   PubMed Web of Science ®Google Scholar
• Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393(10187):2222–2232. doi:10.1016/S0140-6736(19)30420-9
   PubMed Web of Science ®Google Scholar
• Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394(10207):1437–1449. doi:10.1016/S0140-6736(19)31793-3
   PubMed Web of Science ®Google Scholar
• Jones SM, Sicherer SH, Burks AW, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–1252 e1249. doi:10.1016/j.jaci.2016.08.017
   PubMed Web of Science ®Google Scholar
• Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–1079. doi:10.1016/j.jaci.2005.08.027
   PubMed Web of Science ®Google Scholar
• Enrique E, Malek T, Pineda F, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol. 2008;100(3):283–284. doi:10.1016/S1081-1206(10)60456-5
   PubMed Web of Science ®Google Scholar
• Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64(6):876–883. doi:10.1111/j.1398-9995.2008.01921.x
   PubMed Web of Science ®Google Scholar
• Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–646 e641. doi:10.1016/j.jaci.2010.12.1083
   PubMed Web of Science ®Google Scholar
• Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2019;144(5):1320–1326.e1. doi:10.1016/j.jaci.2019.07.030
   Web of Science ®Google Scholar
• Bene J, Ley D, Roboubi R, Gottrand F, Gautier S. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. Ann Allergy Asthma Immunol. 2016;116(6):583–584. doi:10.1016/j.anai.2016.03.017
   Web of Science ®Google Scholar
• Kawashima K, Ishihara S, Masuhara M, et al. Development of eosinophilic esophagitis following sublingual immunotherapy with cedar pollen extract: a case report. Allergol Int. 2018;67(4):515–517. doi:10.1016/j.alit.2018.03.003
   Web of Science ®Google Scholar
• Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy. J Allergy Clin Immunol Pract. 2018;6(2):457–465 e454. doi:10.1016/j.jaip.2017.05.006
   PubMed Web of Science ®Google Scholar
• Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–1282. doi:10.1016/j.jaci.2014.11.005
   Web of Science ®Google Scholar
• Investigators PGoC, Vickery BP, Vereda A, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.
   PubMed Web of Science ®Google Scholar
• El-Qutob D, Reche P, Subiza JL, Fernandez-Caldas E. Peptide-based allergen specific immunotherapy for the treatment of allergic disorders. Recent Pat Inflamm Allergy Drug Discov. 2015;9(1):16–22. doi:10.2174/1872213X09666150302105555
   Google Scholar
• Prickett SR, Hickey PL, Bingham J, et al. Safety and tolerability of a novel peptide-based immunotherapy for peanut allergy. J Allergy Clin Immunol. 2019;143(2):AB431. doi:10.1016/j.jaci.2018.12.975
   Web of Science ®Google Scholar
• A study to evaluate safety, tolerability and immune response in adolescents allergic to peanut after receiving intradermal administration of ASP0892 (ARA-LAMP-vax), a single multivalent peanut (Ara h1, h2, h3) lysosomal associated membrane protein DNA plasmid vaccine. Available from: https://ClinicalTrials.gov/show/NCT03755713. Accessed January 13, 2021.
   Google Scholar
• A study to evaluate safety, tolerability and immune response in adults allergic to peanut after receiving intradermal or intramuscular administration of ASP0892 (ARA-LAMP-vax), a single multivalent peanut (Ara h1, h2, h3) lysosomal associated membrane protein DNA plasmid vaccine. Available from: https://ClinicalTrials.gov/show/NCT02851277. Accessed January 13, 2021.
   Google Scholar
• Scheiblhofer S, Thalhamer J, Weiss R. DNA and mRNA vaccination against allergies. Pediatr Allergy Immunol. 2018;29(7):679–688. doi:10.1111/pai.12964
   Web of Science ®Google Scholar
• MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873–881 e878. doi:10.1016/j.jaci.2016.08.010
   PubMed Web of Science ®Google Scholar
• Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy. 2019;49(10):1328–1341. doi:10.1111/cea.13469
   Web of Science ®Google Scholar
• Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic participants. Available from: https://ClinicalTrials.gov/show/NCT03881696. Accessed January 13, 2021.
   Google Scholar
• Sastre J, Davila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–150. doi:10.18176/jiaci.0254
   PubMed Web of Science ®Google Scholar
• Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to AR101 (peanut oral immunotherapy). Available from: https://ClinicalTrials.gov/show/NCT03682770. Accessed January 13, 2021.
   Google Scholar
• Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy. Available from: https://ClinicalTrials.gov/show/NCT03793608. Accessed January 13, 2021.
   Google Scholar
• Dupilumab and Milk OIT for the Treatment of Cow’s Milk Allergy. Available from: https://ClinicalTrials.gov/show/NCT04148352. Accessed January 13, 2021.
   Google Scholar